Abiraterone Inhibits CYP17 and decreases serum testosterone and other androgens This helps in the treatment of Androgen sensitive prostatic carcinoma patients
Composition: Each tablet contains Abiraterone acetate 250 mg.
Indication: In combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.
Dosage and administration: Recommended dose: 1000 mg administered orally once daily in combination with prednisone 5 mg administered orally twice daily; must be taken on an empty stomach;
For patients with baseline moderate hepatic impairment (Child-Pugh Class B): reduce the starting dose to 250 mg once daily.